The potential role of non-steroidal anti-inflammatory drugs in treating Alzheimer's disease

Expert Opinion on Investigational Drugs

Volumn 13, Issue 11, 2004, Pages 1469-1481

  Imbimbo, Bruno P ^a  

^a Research and Development Department   (Italy)

Author keywords

secretase; Alzheimer's disease; Amyloid ; Non steroidal anti inflammatory drugs

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; AMYLOID BETA PROTEIN; CELECOXIB; CHOLINERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DAPSONE; DICLOFENAC; DIFLUNISAL; DP 155; FENOPROFEN; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; GAMMA SECRETASE; HYDROXYCHLOROQUINE SULFATE; IBUPROFEN; INDOMETACIN; INDOMETACIN DERIVATIVE; KETOPROFEN; LEVO FLURBIPROFEN; MECLOFENAMIC ACID; MISOPROSTOL; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULINDAC; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADULT; AGED; ALLOSTERISM; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; DUODENUM ULCER; ENZYME ACTIVITY; ENZYME INHIBITION; GASTROINTESTINAL TOXICITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; OUTCOMES RESEARCH; PATHOGENESIS; REVIEW; RISK ASSESSMENT; STOMACH ULCER; TRANSGENIC MOUSE; TREATMENT PLANNING;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPARTIC ENDOPEPTIDASES; CLINICAL TRIALS; ENDOPEPTIDASES; HUMANS;

EID: 8844270149     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.13.11.1469     Document Type: Review

References (71)

1. DOODY RS, STEVENS JC, BECK C et al.: Practice parameter: management of dementia (an evidence-based review). Neurology (2001) 56:1154-1166.
2. REISBERG B, DOODY R, STOFFLER A, SCHMITT F, FERRIS S, MOBIUS HJ: Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. (2003) 348:1333-1341.
3. HARDY J, SELKOE DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science (2002) 297:353-356.
4. GONG Y, CHANG L, VIOLA KL et al.: Alzheimer's disease-affected brain: presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss. Proc. Natl. Acad. Sci. USA (2003) 100:10417-10422.
5. IN T'VELD BA, RUITENBERG A, HOFMAN A et al.: Nonsteroidal antiinflammatory drugs and the risk of Alzheimer's disease. N. Engl. J. Med. (2001) 345:515-1521.
6. ETMINAN M, GILL S, SAMII A: Effect of non-steroidal anti-inflammatory drugs on risk of Alzheimer's disease: systematic review and meta-analysis of observational studies. Br. Med. J. (2003) 327:128-132.
7. CORNELIUS C, FASTBOM J, WINBLAD B, VIITANEN M: Aspirin, NSAIDs, risk of dementia, and influence of the apolipoprotein E E4 allele in an elderly population. Neuroepidemiology (2004) 23 135-143.
8. BRETELER MMB, IN HET VELD B, HOFMAN A, STRICHER BH: Aβ-42 peptide lowering NSAIDs and Alzheimer's disease. Neurobiol. Aging (2002) 23:S286.
9. LANDI F, CESARI M, ONDER G, RUSSO A, TORRE S, BERNABEI R: Non-steroidal anti-inflammatory drug (NSAID) use and Alzheimer's disease in community-dwelling elderly patients. Am. J. Geriatr. Psychiatry (2003) 11:179-185.
10. ZANDI PP, SZEKELY CA, GREEN RC, BREITNER JC, WELSH-BOHMER KA: Pooled analysis of the association between different NSAIDs and AD: preliminary findings. Neurobiol. Aging (2004) 25:S5 (Abstract S1-03-03).
11. McGEER PL, McGEER EG: Inflammation, autotoxicity and Alzheimer's disease. Neurobiol. Aging (2001) 22:799-809.
12. BLASKO I, VEERHUIS R, STAMPFER-KOUNTCHEV M, SAURWEIN-TEISSL M, EIKELENBOOM P, GRUBECK-LOEBENSTEIN B: Costimulatory effects of interferon-γ and interleukin-1β or tumor necrosis factor α on the synthesis of Aβ1-40 and Aβ1-42 by human astrocytes. Neurobiol. Dis. (2000) 7:682-689.
13. AISEN PS, DAVIS KL: Inflammatory mechanisms in Alzheimer's disease. Implications for therapy. Am. J. Psychiatr. (1994) 151 1105-1113.
14. ROGERS J, KIRBY LC, HEMPELMAN SR et al.: Clinical trial of indomethacin in Alzheimer's disease. Neurology (1993) 43 1609-1611.
15. SCHARF S, MANDER A, UGONI A, VAJDA F, CHRISTOPHIDIS NP: A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology (1999) 53:197-201.
16. AISEN PS, DAVIS KL, BERG JD et al.: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's disease Cooperative Study. Neurology (2000) 54:588-593.
17. VAN GOOL WA, WEINSTEIN HC, SCHELTENS P, WALSTRA GJ, SCHELTENS PK: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: an 18-month randomised, double-blind, placebo-controlled study. Lancet (2001) 358:455-460.
18. McGEER PL, HARADA N, KIMURA H, McGEER EG, SCHULZER M: Prevalence of dementia amongst elderly Japanese with leprosy: apparent effect of chronic drug therapy. Dementia (1992) 3:146-149.
19. BAIN A: Alzheimer's disease. Phase II trial results reported. Immune Network Ltd (2002) (Press release).
20. McGEER PL: Cyclo-oxygenase-2 inhibitors: rationale and therapeutic potential for Alzheimer's disease. Drugs Aging (2000) 17:1-11.
21. HO L, PUROHIT D, HAROUTUNIAN V et al.: Neuronal cyclooxygenase 2 expression in the hippocampal formation as a function of the clinical progression of Alzheimer's disease. Arch. Neurol. (2001) 58:487-492.
22. ANDREASSON KI, SAVONENKO A, VIDENSKY S et al.: Age-dependent cognitive deficits and neuronal apoptosis in cyclooxygenase-2 transgenic mice. J. Neurosci. (2001) 21 8198-8209.
23. SAINATI SM, INGRAM DM, TALWALKER S, GEIS G: Results of a double-blind, randomized, placebo-controlled study of celecoxib in the treatment of progression of Alzheimer's disease. 6th International Stockholm/Springfield Symposium on Advances in Alzheimer Therapy. Stockholm, Sweden (2000) 180.
24. AISEN P, SCHAFER KA, GRUNDMAN M et al.: Effects of rofecoxib or naproxen versus placebo on Alzheimer's disease progression. JAMA (2003) 289:2819-2826.
25. REINES SA, BLOCK GA, MORRIS JC et al.: Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology (2004) 62:66-71.
26. LAUNER LJ: Nonsteroidal anti-inflammatory drugs and Alzheimer's disease: what's next? JAMA (2003) 289:2865-2867.
27. VISSER H, THAL L, FERRIS S et al.: A randomized, double-blind, placebo-controlled study of rofecoxib in patients with mild cognitive impairment. ACNP 42nd Annual Meeting. San Juan, Puerto Rico (2003).
28. TABET N, FELDMAND H: Ibuprofen for Alzheimer's disease. Cochrane Database Syst Rev. (2003) 2:CD004031.
29. MARTIN BK, MEINERT CL, BREITNER JC: Double placebo design in a prevention trial for Alzheimer's disease. Control Clin. Trials (2002) 23:93-99.
30. WEGGEN S, ERIKSEN JL, DAS P et al.: A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature (2001) 414:212-216.
31. MORIHARA T, CHU T, UBEDA O, BEECH W, COLE GM: Selective inhibition of Aβ42 production by NSAID R-enantiomers. J. Neurochem. (2002) 83:1009-1012.
32. TAKAHASHI Y, HAYASHI I, TOMINARI Y et al.: Sulindac sulphide is a noncompetitive γ-secretase inhibitor that preferentially reduces Aβ42 generation. J. Biol. Chem. (2003 278 18664-18670.
33. ERIKSEN JL, SAGI SA, SMITH TE et al.: NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo. J. Clin. Invest. (2003) 112: 440-449.
34. GASPARINI L, RUSCONI L, XU H, DEL SOLDATO P, ONGINI E: Modulation of β-amyloid metabolism by non-steroidal anti-inflammatory drugs in neuronal cell cultures. J. Neurochem. (2004) 88 337-348.
35. LIM GP, YANG F, CHEN P et al.: Ibuprofen suppresses plaque pathology in a mouse model for Alzheimer's disease. J. Neurosci. (2000) 20:5709-5714.
36. LIM GP, YANG F, CHU T et al.: Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice. Neurobiol. Aging (2001) 22:983-991.
37. YAN Q, ZHANG J, LIU H et al.: Anti-inflammatory drug therapy alters β-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. (2003) 23:7504-7509.
38. DEDEOGLU A, CHOI J, CORMIER K et al.: Ibuprofen reduces Aβ(1-42)/Aβ(1-40) ratio in Alzheimer mice cortex at ages where no metabolic changes are noted by magnetic resonance spectroscopy. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 295.2).
39. JANTZEN PT, CONNOR KE, DICARLO G et al.: Microglial activation and β-amyloid deposit reduction caused by a nitric-oxide-releasing non-steroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci. (2002) 22:2246-2254.
40. VAN GROEN T: HCT 1026 study in transgenic mice. Symposium on Neuroinflammation as a Therapeutic Target in Neurodegeneration. Catania, Italy (2004).
41. QUINN J, MONTINE T, MORROW J, WOODWARD WR, KULHANEK D, ECKENSTEIN F: Inflammation and cerebral amyloidosis are disconnected in an animal model of Alzheimer's disease. J. Neuroimmunol. (2003) 137:32-41.
42. LANZ TA, FICI GJ, MERCHANT KM: Lack of specific Aβ(1-42) suppression by NSAIDs in young, plaque-free Tg2576 mice and in guinea pig neuronal cultures. J. Pharmacol. Exp. Ther. (2004) (In Press).
43. DEMATTOs RB, BALES KR, CUMMINS DJ, PAUL SM, HOLTZMAN DM: Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science (2002) 295 2264-2267.
44. SPARKS L: Benefit of atorvastatin in the treatment of AD. 8th International Montreal/Springfield Symposium on Advances in Alzheimer Therapy. Montreal, Canada (2004).
45. ERIKSEN JL, NICOLLE MM, PRESCOTT S et al.: Chronic treatment of transgenic APP mice with R-flurbiprofen. Annual Meeting of the Society for Neuroscience. New Orleans, LA, USA (2003).
46. HAUSS-WEGRZYNIAK B, VRANIAK P, WENK GL: The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol. Aging (1999) 20:305-313.
47. RICHARDSON RL, KIM EM, SHEPHARD RA, GARDINER T, CLEARY J, O'HARE E: Behavioural and histopathological analyses of ibuprofen treatment on the effect of aggregated Aβ(1-42) injections in the rat. Brain Res. (2002) 954:1-10.
48. MESCHES MH, GEMMA C, VENG LM et al.: Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiol Aging (2004) 25:315-324.
49. SAGI SA, WEGGEN S, ERIKSEN J, GOLDE TE, KOO EH: The non-cyclooxygenase targets of non-steroidal anti-inflammatory drugs, lipoxygenases, peroxisome proliferator-activated receptor, inhibitor of κB kinase, and NFκB, do not reduce amyloid β42 production. J. Biol. Chem. (2003) 278:31825-31830.
50. SASTRE M, DEWACHTER I, LANDRETH GE et al.: Nonsteroidal anti-inflammatory drugs and peroxisome proliferator-activated receptor-γ agonists modulate immunostimulated processing of amyloid precursor protein through regulation of β-secretase. J. Neurosci. (2003) 23:9796-9804.
51. SUNG S, YANG H, URYU K et al.: Modulation of NF-κB activity by indomethacin influences Aβ levels but not APP metabolism in a model of Alzheimer's disease. Am. J. Pathol. (2004) (in press).
52. ELLERBROCK BR, FLECK TJ, LANDRUM CS et al.: NSAID modulators of the γ-secretase show similar potencies at inhibition of Aβ1-42 and induction of Aβ1-38 as measured by a novel neoepitope-specific ELISA. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 667.10).
53. WEGGEN S, ERIKSEN JL, SAGI SA et al.: Evidence that nonsteroidal anti-inflammatory drugs decrease amyloid β42 production by direct modulation of γ-secretase activity. J. Biol. Chem. (2003) 278:31831-31837.
54. BEHER D, CLARKE EE, WRIGLEY JD et al.: Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site-evidence for an allosteric mechanism. J. Biol. Chem. (2004) (in press).
55. SAGI SA, ERIKSEN JL, BEARD J et al.: Aβ42 lowering NSAIDs can be converted to Aβ42 raising agents by simple structural modifications. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 876.14).
56. ZHOU Y, SU Y, LI B et al.: Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Aβ42 by inhibiting Rho. Science (2003) 302:1215-1217.
57. WEGGEN S, BERDEAUX R, KUMMER MP et al.: Inhibitors of the Rho effector Rho-kinase (ROCK) modulate Aβ secretion but lack selectivity for Aβ42. Neurobiol. Aging (2004) 25:S583 (Abstract P4-380).
58. LEWIS HD, PEREZ REVUELTA BI, NADIN A et al.: Catalytic site-directed γ-secretase complex inhibitors do not discriminate pharmacologically between Notch S3 and β-APP cleavages. Biochemistry (2003) 42:7580-7586.
59. HADLAND BK, MANLEY NR, SU D et al.: γ-secretase inhibitors repress thymocyte development. Proc. Natl. Acad. Sci. USA (2001) 98:7487-7491.
60. WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. (2004) 279:2876-2882.
61. MILANO J, McKAY J, DAGENAIS C et al.: Modulation of Notch processing by γ-secretase inhibitors causes intestinal goblet cell metaplasia and induction of genes known to specify gut secretory lineage differentiation. Toxicol. Sci. (2004) (in press ).
62. WEGGEN S, ERIKSEN JL, SAGI SA, PIETRZIK CU, GOLDE TE, KOO EH: Aβ42-lowering nonsteroidal anti-inflammatory drugs preserve intramembrane cleavage of the amyloid precursor protein (APP) and ErbB-4 receptor and signaling through the APP intracellular domain. J. Biol. Chem. (2003) 278:30748-30754.
63. LABORDE AL, PEACH ML, PAULEY AM et al.: NSAID modulators of the γ-secretase show weak blockade of APP and Notch-gaL4-vp16 release compared to their efficacy at blocking Aβ 1-42 production. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 336.8).
64. NYE JS, PAULEY AM, ELLERBROCK BR et al.: NSAIDs that modulate γ-site cleavages of APP have less potent effects upon the E-site cleavages of APP, Notch and ErbB4.33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 336.9 ).
65. WRIGLEY JDJ, MARTIN ACL, CLARKE EE et al.: Modulation versus inhibition - selected NSAIDs can act as γ secretase inhibitors in vitro. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 295.2).
66. PERINI R, FIORUCCI S, WALLACE JL: Mechanisms of nonsteroidal antiinflammatory drug-induced gastrointestinal injury and repair: a window of opportunity for cyclooxygenase-inhibiting nitric oxide donors. Can. J. Gastroenterol. (2004) 18:229-236.
67. FIORUCCI S, SANTUCCI L, SARDINA M et al.: Effect of HCT 1026, a nitric oxide (NO) releasing derivative of flurbiprofen on gastrointestinal mucosa: a double blind placebo-controlled endoscopic study. Digestive Disease Week Meeting. Boston, MA, USA (2003).
68. TOCCHETTI P, SARDINA M, SANTUS G, DEL SOLDATO P: Cerebrospinal fluid concentration of flurbiprofen after multiple administrations of HCT 1026, a NO-donating derivative of flurbiprofen, in humans. First Congress of the International Society for Vascular Behavioural and Cognitive Disorders. Goteborg, Sweden (2003).
69. FRIEDMAN JE, LEE J, KOH J et al.: The indomethacin phospholipid derivative DP-155 lowers amyloidogenic Aβ42 in human APP transgenic mice. 33rd Annual Meeting of Society of Neuroscience. New Orleans, LA, USA (2003) (Abstract 525.15).
70. IMBIMBO BP, PERETTO I, RADAELLI S et al.: New flurbiprofen analogues, devoid of cyclooxygenase activity, selectively lower β amyloid1-42 secretion. Neurobiol. Aging (2004) 25 S64 (Abstract 03-06-05).
71. CIRRITO JR, HOLTZMAN DM: Amyloid β and Alzheimer's disease therapeutics: the devil may be in the details. J. Clin. Invest. (2003) 112:321-323.